Hyperhomocysteinemia and thrombosis

Hematology/Oncology Clinics of North America

Volumn 17, Issue 1, 2003, Pages 85-102

  Lee, Ray ^a   Frenkel, Eugene P ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; METHIONINE SYNTHASE; NITRIC OXIDE; PYRIDOXINE;

AMINO ACID METABOLISM; DIET SUPPLEMENTATION; DIETARY INTAKE; GENE MUTATION; HUMAN; HYPERHOMOCYSTEINEMIA; LIFESTYLE; METHYLATION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SULFATION; THROMBOEMBOLISM; THROMBOSIS; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VEIN THROMBOSIS; VITAMIN DEFICIENCY;

HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; THROMBOSIS;

EID: 0037321186     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(02)00090-4     Document Type: Review

References (111)

1. Carson NA, Neill DW. Metabolic abnormalities detected in a survey of mentally backward individuals in Northern Ireland. Arch Dis Child 1962;37:505-13.
2. Gerritsen T, Vaughn JG, Waisman HA. The identification of homocystine in the urine. Biochem Biophys Res Commun 1962;9:493-6.
3. McCully KS, Wilson RB. Homocysteine theory of arteriosclerosis. Atherosclerosis 1975;22:215-27.
4. Wilcken DE, Wilcken B, Dudman NP, et al. Homocystinuria - the effects of betaine in the treatment of patients not responsive to pyridoxine. N Engl J Med 1983;309:448-53.
5. Ueland PM. Homocysteine species as components of plasma redox thiol status. Clin Chem 1995;41:340-2.
6. Chambers JC, Ueland PM, Wright M, et al. Investigation of relationship between reduced, oxidized, and protein-bound homocysteine and vascular endothelial function in healthy human subjects. Circ Res 2001;89:187-92.
7. Kang SS, Wong PW, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr 1992;12:279-98.
8. Boushey CJ, Beresford SA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-57.
9. Selhub J. Homocysteine metabolism. Annu Rev Nutr 1999;19:217-46.
10. Mudd SH, Levy HL, Skovby F. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, et al, editors. The metabolic and molecular basis of inherited disease. New York: McGraw-Hill; 1995. p. 1279-327.
11. Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 1985;37:1-31.
12. Gibson JB, Carson NAJ, Neill DW. Pathological findings in homocystinuria. J Clin Pathol 1964;17:427-37.
13. Kang SS, Zhou J, Wong PW, et al. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 1988;43:414-21.
14. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-3.
15. Pepe G, Rickards O, Vanegas OC, et al. Prevalence of factor V Leiden mutation in non-European populations. Thromb Haemost 1997;77:329-31.
16. Hessner MJ, Luhm RA, Pearson SL, et al. Prevalence of prothrombin G20210A, factor V G1691A (Leiden), and methylenetetrahydrofolate reductase (MTHFR) C677T in seven different populations determined by multiplex allele-specific PCR. Thromb Haemost 1999;81:733-8.
17. Zheng YZ, Tong J, Do XP, et al. Prevalence of methylenetetrahydrofolate reductase C677T and its association with arterial and venous thrombosis in the Chinese population. Br J Haematol 2000;109:870-4.
18. Conroy JM, Trivedi G, Sovd T, et al. The allele frequency of mutations in four genes that confer enhanced susceptibility to venous thromboembolism in an unselected group of New York State newborns. Thromb Res 2000;99:317-24.
19. Ma J, Stampfer MJ, Hennekens CH, et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 1996;94:2410-6.
20. Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996;93:7-9.
21. Brattstrom L, Wilcken DE, Ohrvik J, et al. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 1998;98:2520-6.
22. Guttormsen AB, Ueland PM, Nesthus I, et al. Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (≥40 micromol/liter): the Hordaland Homocysteine Study. J Clin Invest 1996;98:2174-83.
23. Gaustadnes M, Rudiger N, Rasmussen K, et al. Intermediate and severe hyperhomocysteinemia with thrombosis: a study of genetic determinants. Thromb Haemost 2000;83:554-8.
24. van der Put NM, Gabreels F, Stevens EM, et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 1998;62:1044-51.
25. Hanson NQ, Aras O, Yang F, et al. C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase gene: incidence and effect of combined genotypes on plasma fasting and post-methionine load homocysteine in vascular disease. Clin Chem 2001;47:661-6.
26. Dekou V, Whincup P, Papacosta O, et al. The effect of the C677T and A1298C polymorphisms in the methylenetetrahydrofolate reductase gene on homocysteine levels in elderly men and women from the British regional heart study. Atherosclerosis 2001;154:659-66.
27. Leclerc D, Campeau E, Goyette P, et al. Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders. Hum Mol Genet 1996;5:1867-74.
28. Tsai MY, Welge BG, Hanson NQ, et al. Genetic causes of mild hyperhomocysteinemia in patients with premature occlusive coronary artery diseases. Atherosclerosis 1999;143:163-70.
29. Tsai MY, Bignell M, Yang F, et al. Polygenic influence on plasma homocysteine: association of two prevalent mutations, the 844ins68 of cystathionine beta-synthase and A(2756)G of methionine synthase, with lowered plasma homocysteine levels. Atherosclerosis 2000;149:131-7.
30. Zhang G, Dai C. Gene polymorphisms of homocysteine metabolism-related enzymes in Chinese patients with occlusive coronary artery or cerebral vascular diseases. Thromb Res 2001;104:187-95.
31. Tsai MY, Garg U, Key NS, et al. Molecular and biochemical approaches in the identification of heterozygotes for homocystinuria. Atherosclerosis 1996;122:69-77.
32. Tsai MY, Yang F, Bignell M, et al. Relation between plasma homocysteine concentration, the 844ins68 variant of the cystathionine beta-synthase gene, and pyridoxal-5′-phosphate concentration. Mol Genet Metab 1999;67:352-6.
33. Wang XL, Duarte N, Cai H, et al. Relationship between total plasma homocysteine, polymorphisms of homocysteine metabolism related enzymes, risk factors and coronary artery disease in the Australian hospital-based population. Atherosclerosis 1999;146:133-40.
34. Kluijtmans LA, Boers GH, Trijbels FJ, et al. A common 844INS68 insertion variant in the cystathionine beta-synthase gene. Biochem Mol Med 1997;62:23-5.
35. de Franchis R, Fermo I, Mazzola G, et al. Contribution of the cystathionine beta-synthase gene (844ins68) polymorphism to the risk of early-onset venous and arterial occlusive disease and of fasting hyperhomocysteinemia. Thromb Haemost 2000;84:576-82.
36. Delvin EE, Rozen R, Merouani A, et al. Influence of methylenetetrahydrofolate reductase genotype, age, vitamin B-12, and folate status on plasma homocysteine in children. Am J Clin Nutr 2000;72:1469-73.
37. Todesco L, Angst C, Litynski P, et al. Methylenetetrahydrofolate reductase polymorphism, plasma homocysteine and age. Eur J Clin Invest 1999;29:1003-9.
38. Jacques PF, Bostom AG, Wilson PW, et al. Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. Am J Clin Nutr 2001;73:613-21.
39. Lussier-Cacan S, Xhignesse M, Piolot A, et al. Plasma total homocysteine in healthy subjects: sex-specific relation with biological traits. Am J Clin Nutr 1996;64:587-93.
40. Morris MS, Jacques PF, Selhub J, et al. Total homocysteine and estrogen status indicators in the Third National Health and Nutrition Examination Survey. Am J Epidemiol 2000;152:140-8.
41. Hak AE, Polderman KH, Westehdorp IC, et al. Increased plasma homocysteine after menopause. Atherosclerosis 2000;149:163-8.
42. Walsh BW, Paul S, Wild RA, et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized. controlled trial. J Clin Endocrinol Metab 2000;85:214-8.
43. Bonnette RE, Caudill MA, Boddie AM, et al. Plasma homocyst(e)ine concentrations in pregnant and nonpregnant women with controlled folate intake. Obstet Gynecol 1998;92:167-70.
44. Andersson A, Hultberg B, Brattstrom L, et al. Decreased serum homocysteine in pregnancy. Eur J Clin Chem Clin Biochem 1992;30:377-9.
45. Varela-Moreiras G. Nutritional regulation of homocysteine: effects of drugs. Biomed Pharmacother 2001;55:448-53.
46. Christensen B, Mosdol A, Retterstol L, et al. Abstention from filtered coffee reduces the concentrations of plasma homocysteine and serum cholesterol - a randomized controlled trial. Am J Clin Nutr 2001;74:302-7.
47. Nygard O, Vollset SE, Refsum H, et al. Total plasma homocysteine and cardiovascular risk profile: the Hordaland Homocysteine Study. JAMA 1995;274:1526-33.
48. Stabler SP, Marcell PD, Podell ER, et al. Elevation of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by capillary gas chromatography-mass spectrometry. J Clin Invest 1988;81:466-74.
49. Chu RC, Hall CA. The total serum homocysteine as an indicator of vitamin B12 and folate status. Am J Clin Pathol 1988;90:446-9.
50. Andersson A, Brattstrom L, Israelsson B, et al. Plasma homocysteine before and after methionine loading with regard to age, gender, and menopausal status. Eur J Clin Invest 1992;22:79-87.
51. Hvas AM, Ellegaard J, Nexo E. Vitamin B12 treatment normalizes metabolic markers but has limited clinical effect: a randomized placebo-controlled study. Clin Chem 2001;47:1396-404.
52. Ubbink JB, Vermaak WJ, van der MA, et al. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr 1993;57:47-53.
53. Mansoor MA, Kristensen O, Hervig T, et al. Plasma total homocysteine response to oral doses of folic acid and pyridoxine hydrochloride (vitamin B6) in healthy individuals: oral doses of vitamin B6 reduce concentrations of serum folate. Scand J Clin Lab Invest 1999;59:139-46.
54. Kang SS, Wong PW, Norusis M. Homocysteinemia due to folate deficiency. Metabolism 1987;36:458-62.
55. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ 1998;316:894-8.
56. Bostom AG, Kronenberg F, Jacques PF, et al. Proteinuria and plasma total homocysteine levels in chronic renal disease patients with a normal range serum creatinine: critical impact of true glomerular filtration rate. Atherosclerosis 2001;159:219-23.
57. Davies L, Wilmshurst EG, McElduff A, et al. The relationship among homocysteine, creatinine clearance, and albuminuria in patients with type 2 diabetes. Diabetes Care 2001;24:1805-9.
58. Wrone EM, Zehnder JL, Homberger JM, et al. An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease. Kidney Int 2001;60:1106-13.
59. Tremblay R, Bonnardeaux A, Geadah D, et al. Hyperhomocysteinemia in hemodialysis patients: effects of 12-month supplementation with hydrosoluble vitamins. Kidney Int 2000;58:851-8.
60. Fodinger M, Wagner OF, Horl WH, et al. Recent insights into the molecular genetics of the homocysteine metabolism. Kidney Int Suppl 2001;78:S238-42.
61. Kaplan LN, Mamer OA, Hoffer LJ. Parenteral vitamin B12 reduces hyperhomocysteinemia in end-stage renal disease. Clin Invest Med 2001;24:5-11.
62. Thambyrajah J, Landray MJ, McGlynn FJ, et al. Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure? Circulation 2000;102:871-5.
63. Sunder-Plassmann G, Fodinger M, Buchmayer H, et al. Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: results of the Vienna multicenter study. J Am Soc Nephrol 2000;11:1106-16.
64. den Heijer M, Rosendaal FR, Blom HJ, et al. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost 1998;80:874-7.
65. Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med 1998;158:2101-6.
66. De Stefano V, Casorelli I, Rossi E, et al. Interaction between hyperhomocysteinemia and inherited thrombophilic factors in venous thromboembolism. Semin Thromb Hemost 2000;26:305-11.
67. Fermo I, Vigano DS, Paroni R, et al. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med 1995;123:747-53.
68. den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996;334:759-62.
69. Eichinger S, Stumpflen A, Hirschl M, et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 1998;80:566-9.
70. Ocal IT, Sadeghi A, Press RD. Risk of venous thrombosis in carriers of a common mutation in the homocysteine regulatory enzyme methylenetetrahydrofolate reductase. Mol Diagn 1997;2:61-8.
71. Ridker PM, Hennekens CH, Selhub J, et al. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 1997;95:1777-82.
72. Hsu LA, Ko YL, Wang SM, et al. The C677T mutation of the methylenetetrahydrofolate reductase gene is not associated with the risk of coronary artery disease or venous thrombosis among Chinese in Taiwan. Hum Hered 2001;51:41-5.
73. von Depka M, Nowak-Gottl U, Eisert R, et al. Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. Blood 2000;96:3364-8.
74. Franco RF, Morelli V, Lourenco D, et al. A second mutation in the methylenetetrahydrofolate reductase gene and the risk of venous thrombotic disease. Br J Haematol 1999;105:556-9.
75. Brown K, Luddington R, Baglin T. Effect of the MTHFRC677T variant on risk of venous thromboembolism: interaction with factor V Leiden and prothrombin (F2G20210A) mutations. Br J Haematol 1998;103:42-4.
76. Kluijtmans LA, den Heijer M, Reitsma PH, et al. Thermolabile methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep-vein thrombosis. Thromb Haemost 1998;79:254-8.
77. Alhenc-Gelas M, Arnaud E, Nicaud V, et al. Venous thromboembolic disease and the prothrombin, methylene tetrahydrofolate reductase and factor V genes. Thromb Haemost 1999;81:506-10.
78. Moller J, Nielsen GM, Tvedegaard KC, et al. A meta-analysis of cerebrovascular disease and hyperhomocysteinaemia. Scand J Clin Lab Invest 2000;60:491-9.
79. Bostom AG, Rosenberg IH, Silbershatz H, et al. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. Ann Intern Med 1999;131:352-5.
80. Wu AH, Tsongalis GJ. Correlation of polymorphisms to coagulation and biochemical risk factors for cardiovascular diseases. Am J Cardiol 2001;87:1361-6.
81. Voetsch B, Damasceno BP, Camargo EC, et al. Inherited thrombophilia as a risk factor for the development of ischemic stroke in young adults. Thromb Haemost 2000;83:229-33.
82. Lopaciuk S, Bykowska K, Kwiecinski H, et al. Factor V Leiden, prothrombin gene G20210A variant, and methylenetetrahydrofolate reductase C677T genotype in young adults with ischemic stroke. Clin Appl Thromb Hemost 2001;7:346-50.
83. Meiklejohn DJ, Vickers MA, Dijkhuisen R, et al. Plasma homocysteine concentrations in the acute and convalescent periods of atherothrombotic stroke. Stroke 2001;32:57-62.
84. Cleophas TJ, Homstra N, van Hoogstraten B, et al. Homocysteine, a risk factor for coronary artery disease or not? a meta-analysis. Am J Cardiol 2000;86:1005-9.
85. Christen WG, Ajani UA, Glynn RJ, et al. Blood levels of homocysteine and increased risks of cardiovascular disease: causal or casual? Arch Intern Med 2000;160:422-34.
86. Dudman NP. An alternative view of homocysteine. Lancet 1999;354:2072-4.
87. Wall RT, Harlan JM, Harker LA, et al. In vitro effects of hyperlipoproteinemic sera on human endothelium: inhibition of endothelial cell migration by familial hypercholesterolemic sera. Thromb Res 1980;17:753-65.
88. Rakhit RD, Marber MS. Nitric oxide: an emerging role in cardioprotection? Heart 2001;86:368-72.
89. Stamler JS, Osborne JA, Jaraki O, et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993;91:308-18.
90. Stuhlinger MC, Tsao PS, Her JH, et al. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 2001;104:2569-75.
91. Schlaich MP, John S, Jacobi J, et al. Mildly elevated homocysteine concentrations impair endothelium dependent vasodilation in hypercholesterolemic patients. Atherosclerosis 2000;153:383-9.
92. Tawakol A, Omland T, Gerhard M, et al. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997;95:1119-21.
93. Chambers JC, Ueland PM, Obeid OA, et al. Improved vascular endothelial function after oral B vitamins: an effect mediated through reduced concentrations of free plasma homocysteine. Circulation 2000;102:2479-83.
94. Woo KS, Chook P, Lolin YI, et al. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 1997;96:2542-4.
95. Jakubowski H. Translational accuracy of aminoacyl-tRNA synthetases: implications for atherosclerosis. J Nutr 2001;131:2983S-7S.
96. Jakubowski H. Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J 1999;13:2277-83.
97. Undas A, Williams EB, Butenas S, et al. Homocysteine inhibits inactivation of factor Va by activated protein C. J Biol Chem 2001;276:4389-97.
98. Jakubowski H, Zhang L, Bardeguez A, et al. Homocysteine thiolactone and protein homocysteinylation in human endothelial cells: implications for atherosclerosis. Circ Res 2000;87:45-51.
99. Fryer RH, Wilson BD, Gubler DB, et al. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb 1993;13:1327-33.
100. Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest 1986;77:1909-16.
101. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991;88:1906-14.
102. Hayashi T, Honda G, Suzuki K. An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells. Blood 1992;79:2930-6.
103. Hajjar KA. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 1993;91:2873-9.
104. Landgren F, Israelsson B, Lindgren A, et al. Plasma homocysteine in acute myocardial infarction: homocysteine-lowering effect of folic acid. J Intern Med 1995;237:381-8.
105. den Heijer M, Brouwer IA, Bos GM, et al. Vitamin supplementation reduces blood homocysteine levels: a controlled trial in patients with venous thrombosis and healthy volunteers. Arterioscler Thromb Vasc Biol 1998;18:356-61.
106. McKinley MC, McNulty H, McPartlin J, et al. Low-dose vitamin B-6 effectively lowers fasting plasma homocysteine in healthy elderly persons who are folate and riboflavin replete. Am J Clin Nutr 2001;73:759-64.
107. Wald NJ, Watt HC, Law MR, et al. Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. Arch Intern Med 1998;158:862-7.
108. Malinow MR, Duell PB, Hess DL, et al. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med 1998;338:1009-15.
109. Malinow MR, Nieto FJ, Kruger WD, et al. The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. Arterioscler Thromb Vasc Biol 1997;17:1157-62.
110. Woodside JV, Yarnell JW, McMaster D, et al. Effect of B-group vitamins and antioxidant vitamins on hyperhomocysteinemia: a double-blind, randomized, factorial-design, controlled trial. Am J Clin Nutr 1998;67:858-66.
111. van Guldener C, Janssen MJ, de Meer K, et al. Effect of folic acid and betaine on fasting and postmethionine-loading plasma homocysteine and methionine levels in chronic hemodialysis patients. J Intern Med 1999;245:175-83.